trastuzumab
( trass-TOO-zoo-mab )
Other Name(s): Herceptin®; Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Appearance: Clear, colourless solution
mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Nov 2022
Eligibility Forms
Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast CancerPatient Info Sheet
Sep 2022
What it is used for
For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication. See our biosimilar pamphlet for more information.